Comparing Adial Pharmaceuticals (NASDAQ:ADIL) & SeaStar Medical (NASDAQ:ICUCW)

Adial Pharmaceuticals (NASDAQ:ADIL) and SeaStar Medical (NASDAQ:ICUCW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Valuation & Earnings

This table compares Adial Pharmaceuticals and SeaStar Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$13.20 million	($18.75)	-0.13
SeaStar Medical	$881,000.00	N/A	N/A	N/A	N/A

SeaStar Medical has higher revenue and earnings than Adial Pharmaceuticals.

Profitability

This table compares Adial Pharmaceuticals and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-197.73%	-153.71%
SeaStar Medical	N/A	N/A	N/A

Institutional and Insider Ownership

16.4% of Adial Pharmaceuticals shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Adial Pharmaceuticals and SeaStar Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1	1	1	0	2.00
SeaStar Medical	0	0	0	0	0.00

Adial Pharmaceuticals presently has a consensus target price of $22.75, suggesting a potential upside of 828.57%. Given Adial Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Adial Pharmaceuticals is more favorable than SeaStar Medical.

Summary

Adial Pharmaceuticals beats SeaStar Medical on 5 of the 8 factors compared between the two stocks.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.